Mohammed Haneefa Nizamudeen Health Canada has authorized Johnson & Johnson's ( NYSE: JNJ ) Rybrevant (amivantamab) along with platinum-based chemotherapy as a first-line treatment for non-small cell lung with a certain mutation. The authorization is for patients with EGFR Exon 20 insertion mutations. The approval was supported by data from the phase 3 PAPILLON study that showed the Rybrevant + chemo combination led to clinically meaningful and statistically significant improvement in progression-free survival and a 60% reduction in the risk of disease progression or death compared to chemo alone.
More on Johnson & Johnson Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return J&J says Carvykti beat standard drugs in late-stage blood cancer trial J&J talc claimants lose bid to block company's bankruptcy bid Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript).
